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osting by EAbstract To control the minimum effective dose, and reduce the number and quantity of admin-
istered potent drugs are unique features of advanced drug delivery in situ forming gel formulation.
The efﬁcacy, consistency, and increasing the application of existing injection therapies can be
enhanced through optimization of controlled released systems by using FDA approved biodegrad-
able PLGA (poly-D,L-lactide-co-glycolide) polymer. The purpose of this study was to develop dif-
ferent in situ forming implant (ISFI) formulations of buprenorphine hydrochloride for post
treatment of drug addicts, acute and chronic pains.
The drug releases from different ISFIs membranes with and without Tween 80 were compared
over a period of time. Kinetic equation followed the Korsmeyer–Peppas model, as the plots showed
high linearity. The inﬂuence of this additive on polymer properties was investigated using differen-
tial scanning calorimetry (DSC), and the membranes structure was studied by X-ray diffractometry
(XRD) and scanning electron microscope (SEM).
Data revealed that Tween 80 modiﬁed the drug release pattern using diffusion mechanism and
decreased the glass transition temperature (Tg) signiﬁcantly. The degree of crystallinity was
decreased after phase inversion which helps the dissolution of drug from membrane. The porosity
of modiﬁed membranes was in accordance with release proﬁles.831 4274530; fax: +98 831
(S.S. Madaeni).
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256 S. Koocheki et al.These ﬁndings suggest four different in situ forming implant formulations which can release var-
ious dose of the buprenorphine hydrochloride in a prolonged time. Also this surfactant can be an
attractive additive for modifying the release rate of drugs from PLGA-based membrane drug deliv-
ery systems.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Biomaterials, which are substances in contact with biological
ﬂuids in diagnostic and therapeutic systems, have to be quali-
ﬁed for some characteristics depending on the features of their
application. For example, to avoid clotting, the devices in car-
diovascular implants must have a deﬁnite size. Accordingly,
characteristics of biomaterials such as size, shape, blood com-
patibility, and porosity must be kept in mind when used. Like-
wise in drug delivery, properties such as drug permeability and
good release are important as well. Therefore, for properties of
biological ﬂuids to be stable, all biomaterial-based membranes
in contact with them must prevent infection and immune re-
sponse, blood clotting, etc. to ensure safety for the patient
(Stamatialis et al., 2008).
One of the members of synthesized biodegradable and
biocompatible copolymers class, which is used in making
resorbable sutures, resorbable surgical clips, and controlled-re-
lease implants, is polylactide–polyglycolide acid (PLGA). This
copolymer which is used for implantable and injectable con-
trolled-release devices in drug delivery systems and also other
copolymers in this class are approved for humans and have a
history of safe use. After PLGA material is introduced to
body, it induces only a minimal inﬂammatory response and
biodegrades by hydrolysis of its ester linkages in order to pro-
duce biocompatible lactic and glycolic acids. Furthermore, the
rate at which PLGA biodegrades is a function of the ratio of
lactide to glycolide (Liu et al., 2010).
Since Loeb and Sourirajan in 1963 developed asymmetric
type membrane, the ﬁeld of membrane science has grown
noticeably. Numerous recent membranes have been produced
for speciﬁc purposes and many of them have been taken to dif-
ferent areas of biomedical industry, e.g., controlled-release and
hemodialysis (Loeb and Sourirajan, 1963; Young et al., 2001).
Dunn et al. in 1990 ﬁrst developed the concept of in situ
forming devices (ISFD) based on polymer precipitation (Dunn
et al., 1990).
In order to inject the device into the body, a solution or sus-
pension must be made by adding the drug to a solution of a
water-insoluble, biodegradable polymer and a biocompatible
organic solvent. After injecting this formulation into the body,
the water-miscible organic solvent dissipates, letting water pen-
etrate into the organic phase. This causes phase inversion and
polymer precipitation, forming a depot at the site of injection
(Packhaeuser et al., 2004). After the solvent is completely dis-
sipated, drug release is controlled by drug properties and poly-
mer, as in the case of any other biodegradable implant. To
reach a desired drug release proﬁle, polymer properties such
as molecular weight, hydrophobicity, and co-monomer ratio
can be adjusted (Ravivarapu et al., 2000). In comparison to
surgically implanted systems, polymer solution delivery
platforms can offer a better and easier administration and pro-
longed release of biopharmaceutical agents as well. Thissystem basically consists of a solution of a biodegradable poly-
mer in a biocompatible solvent in which the bioactive agents
are suspended or dissolved. After delivery is affected by inject-
ing the patient directly, a two-phased, gelled implant is formed.
The reason of this formation is the liquid de-mixing of the
solution caused by contact between the water-insoluble poly-
mer and the aqueous-based physiological surroundings. There-
fore, formation of the device (e.g., polymer membrane carrier)
occurs along with the release of the carried drug. To maintain
drug delivery within a speciﬁc therapeutic dose, it is required to
lower initial burst to achieve prolonged and zero-order release
rate over the lifetime of the in situ forming (ISF) polymeric
membrane (Brodbeck et al., 1999).
ISF membrane is essentially skinless, unlike the traditional
asymmetric membrane. PLGA is used in different divisions of
medicine applications such as scaffold construction for stem cell
growth, membrane preparation and drug delivery systems. N-
Methyl-2-pyrrolidone (NMP) as a common and biological com-
patible solvent for this polymer has beenwidely used in the prep-
aration of PLGA in situ forming membrane (Luan and
Bodmeier, 2006). One of the additives which are used in formu-
lations of ISFmembrane is a surfactant that can be used to cause
a decrease or increase in the release rate of drug and specially for
controlling the burst release. A surfactant is an amphiphilicmol-
ecule consisting of a hydrophobic tail and a hydrophilic head
group. These molecules possess distinct regions of both hydro-
philic and hydrophobic speciﬁcations. The hydrophobic tail
can be a hydrocarbon or ﬂuorocarbon chain of 8 to 18 carbon
atoms. Surface-active agents or surfactants are long chain mol-
ecules, such as soaps and detergents, which accumulate at the
hydrophilic/hydrophobic (water/oil) interface and lower the
surface tension at the interface.
One of the surfactants used for increasing permeation of
water into the implant by changing membrane structure, sur-
face tension and permeability is polyethylene glycol sorbitan
monooleate (Tween 80 a registered trademark of ICI Ameri-
cas, Inc.) (Fox, 2009; Ofokansi et al., 2009; Patel and Vavia,
2007; Wang et al.,2009), Graves et al. (2007) which used Tween
80 as a co-solvent, which increases dissolution rate of an in situ
gel formulation into the phosphate buffer solution. Tween 80
is an excipient that is used to stabilize aqueous formulations
of medications for parenteral administration.
In present study, the performance and characterization of
PLGA/NMP/Water systems based on the release of a small
drug molecule, buprenorphine hydrochloride (Fig. 1A), with
and without Tween 80 (Fig. 1B) as a rate modifying agent
using ISF membranes was investigated. Buprenorphine hydro-
chloride is a synthetic opiate analgesic which has a combina-
tion property of agonist and antagonist. It is used for post
treatment of drug addicts, acute and chronic pains (Hutchings
et al., 2007; Wilding et al., 1996).
Respiratory depression of buprenorphine hydrochloride in
case of high dose delivery, is very low because of its partial
agonist (Schuh and Johanson, 1999).
Figure 1 Chemical structure of buprenorphine HCl (A) and
Tween 80 (B).
Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride 257Opiate receptor afﬁnity and analgesic effect of this drug is
higher than morphine. Because of ﬁrst-pass metabolism in le-
ver and gut the injectable and sublingual tablets are marketed.
Regarding short half-life (2.75 h) of buprenorphine in the
body and limited clinical use (Wang et al., 2009), develop a
continuous release formulations which can increase the appli-
cations of this useful drug in pain management (Johnson
et al., 2005).
A major concern in opioid dependence treatment using
buprenorphine HCl is the drug abuse potential (Johnson
et al., 2005; Singhal et al., 2007), which can be minimized using
in situ forming implant drug delivery system.2. Materials and methods
2.1. Materials
The following chemicals were obtained from commercial sup-
pliers and used as received: poly(D,L-lactide-co-glycolide)
(PLGA 75:25; RG 752H and RG 752S, inherent viscosity
0.2 dL/g, molecular weight 18,000 Da) (Boehringer Ingelheim,
Germany), methanol, glacial acetic acid, ammonium acetate,
sodium hydroxide, potassium dihydrogen phosphate (Merck,
Germany), Buprenorphine HCl (BP) (Diosynth, Netherland),
Tween 80, N-methyl-2-pyrrolidone (NMP) (Sigma–Aldrich,
USA). All chemicals were at least reagent grade.
2.2. Methods
2.2.1. Preparation of in situ forming implant membranes
Two different resomers of PLGA, RG 752S (a capped variety)
and 752H (an uncapped variety), were used in these experi-
ments to achieve different drug release proﬁles. These two
polymers were selected because they are similar except in
polarity, and this difference was expected to result in different
release proﬁles of buprenorphine HCl. Polymer solutions
(ISFDs) were prepared by mixing PLGA with the solvent
(N-methyl-2-pyrrolidone, NMP) in glass vials until the forma-
tion of a clear solution (n= 3). For the ISFDs the polymer
concentration was kept constant at 33% (w/w, based on the
amount of polymer and solvent) (Mohamadnia et al., 2009;
Raﬁenia et al., 2009). Tween 80 (10% w/w, based on the mem-brane) was added to some of the formulations and mixed with
the polymer solution. Buprenorphine HCl was dissolved in the
polymer solution (1% w/w, based on the membrane) and
mixed thoroughly for 120 s using a high speed stirrer (MS3B,
IKA, Germany) at 3000 rpm. This drug concentration was
determined based on maximum miscibility and syringe ability
of the prepared formulation (Table 1).
2.2.2. Kinetics of in vitro drug release
The ISF membranes were incubated in 10 ml of phosphate buf-
fered solution (0.05 M, pH 7.4) in a closed vial at 37 C (n= 3).
At predetermined intervals, 10 ml release medium was taken
and fresh medium replaced to the sample vial. After ﬁltration
(Spanatan, 0.2 lm, Whatman, USA), the amount of buprenor-
phine HCl released into the medium was measured by HPLC
and was expressed as a percentage of the initial buprenorphine
HCl loading in the polymer solutions. Data obtained from re-
lease measurements was ﬁtted to zero order, ﬁrst-order, Higu-
chi’s, and Korsmeyer–Peppas equations (Sakr et al., 2011).
Zero order equation (cumulative amount of drug released
vs time),
Qt ¼ K0t
where Qt is the fraction released at time t and K0 is the zero
order rate constant.
First-order equation (log cumulative percentage of drug
remaining vs time),
logQt ¼ logQ0  K1t=2:303
where Qt is the amount released at time t, Q0 is the initial
amount of drug in solution and K1 is the ﬁrst order rate
constant.
Higuchi’s equation (cumulative percentage of drug released
vs square root of time),
Qt ¼ KH  t1=2
where Qt is the fraction dissolved at time t and KH is the Hig-
uchi dissolution constant.
Korsmeyer–Peppas equation (log cumulative percentage of
drug released vs log time),
Qt
Q1
¼ atn
where Qt is the amount of drug released at time t, Q1 is the
amount of drug released after inﬁnite time, a is the Korsmey-
er–Peppas dissolution rate constant and n is the release
exponent.
2.3. High performance liquid chromatography (HPLC)
Buprenorphine HCl released was analyzed by Agilent HPLC-
1100 series operated by reversed phase C18 column (Nova-
Pak 4 lm, 4.6 mm · 250 mm cartridge, Waters, Ireland).
The mobile phase used was composed of 60:10:0.01 volume ra-
tio of methanol: 1.0% (w/v) ammonium acetate: glacial acetic
acid at a ﬂow rate of 1 ml/min. Twenty microliters of ﬁltered
released samples was injected into HPLC-UV system at
40 C column temperature and detected at 288 nm.
Table 1 Compositions of the in situ formed implant membranes.
Sample Polymer type Polymer (%w/w) Tween 80 (%w/w) Drug content (mg/100 mg membrane)
1 RG 752H 33 0 1.031 ± 0.02
2 RG 752H 33 5 1.012 ± 0.01
3 RG 752H 33 10 1.052 ± 0.03
4 RG 752H 33 15 1.041 ± 0.02
5 RG 752S 33 0 1.038 ± 0.01
6 RG 752S 33 5 1.021 ± 0.02
7 RG 752S 33 10 1.067 ± 0.03
8 RG 752S 33 15 1.044 ± 0.01
Figure 2 Drug release proﬁle of buprenorphine HCl formulation
without Tween 80, RG 752S (h) and RG 752H (n). Data are
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In order to characterize the thermal behavior of the mem-
branes, a Perkin–Elmer DSC 7 apparatus with Pyris software
was used for the determination of the glass temperature tran-
sition (Tg). An accurately weighed amount of the sample
(1.5–3.0 mg) was transferred to an aluminum pan in which a
pinhole was punched in the pan lid, and the sides of the lid
were crimped. A similar empty pan was used as reference.
Samples were scanned from 10 to 70 C at a rate of
10 C min1 under nitrogen gas ﬂow (20 ml min1). The mea-
surements were done in triple and the results were expressed as
the mean of three independent measures. The instrument was
calibrated by indium standard.
2.5. X-ray diffractometry (XRD)
The XRD patterns for amorphous and crystalline powders
were measured by using a PANalytical X-ray diffractometer
(XPERT PRO, PW 3040/60 generator, PIXcel Detector and
X’Pert Data Collector software for automatic powder diffrac-
tion version 2.2i; PANalytical, Almelo, The Netherlands). The
X-ray diffractometer was operated with an anode current of
40 mA and an accelerating voltage of 40 kV. Samples were
slightly pressed on an aluminum sample tray using glass slide
(75 · 25 mm) and exposed to CuKa radiation at diffraction
angles (2h) from 5 to 40 (step size, 0.02; time per step,
40.01 s).
The peak search program of the X’Pert HighScore Plus,
(Version 2.2d, PANalytical B. V., Almelo, The Netherlands)
software was used to locate the peaks in XRD patterns by
detecting the minima from the second derivative of the diffrac-
togram. Intensity maxima were given as Ka1 net peak height
in counts at Ka1 position in degrees.
2.6. Scanning electron microscopy (SEM)
The surfaces of the prepared membranes were studied with a
scanning electron microscope (SEM), VEGAnnTESCAN.
Samples were transferred into the SEM instrument after gold
coating. The SEM studies were carried out at room tempera-
ture with a magniﬁcation of about 1000.
2.7. Statistical analysis
A Student t-test for unpaired samples supported by SPSS 10
for Windows (SPSS, Inc., USA) was used for comparing the
release rate in two formulations over a period of time.3. Results and discussion
The performance of ISF membranes is measured by the initial
drug release from the traditional biodegradable systems. This
burst release is normally credited to the surface associated drug
which is affected by two factors: (I) the casting solution is in-
jected as liquid form. In advance of phase inversion and poly-
mer solidiﬁcation, the drug is released simultaneously with
solvent diffusion out into release medium. This release is
ampliﬁed in particular with drugs, which are high soluble in
water; (II) upon the polymer solidiﬁcation, some of the drug
molecules which are associated with the surface or entrapped
into highly porous membrane are released rapidly. For this
reason, the important factor in the membrane solidiﬁcation
from in situ forming solution is diffusion rate of the organic
solvent from the casting solution into the aqueous release med-
ium and as a result, the burst release. A high solvent diffusion
rate causes a rapid drug release from the polymer casting solu-
tion and rapid polymer precipitation, resulting in the porous
membrane; both enhance initial release.
All the investigated formulations (Table 1) formed a solid
gel as soon as they came in contact with the buffer solution.
The release proﬁles of buprenorphine HCl from PLGA/
NMP with and without Tween 80 (10% w/w) after coagulation
at phosphate buffer are shown in Figs. 2 and 3, respectively. It
can be divided into two different phases, with different release
rates; an initial burst release followed by slower drug releasemean ± SD, n= 3.
Figure 3 Drug release proﬁle of buprenorphine HCl formulation
with Tween 80 (10%w/w), RG 752S (h) and RG 752H (n). Data
are mean ± SD, n= 3.
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signiﬁcant differences (P< 0.05) in drug release from RG
752S and RG 752H with and without Tween 80 after the ﬁrst
days they came into contact with the buffer.
Drug release from all of the formulations was linear from
day 3 until the end (Figs. 2 and 3). The drug release proﬁles
obtained for RG 752H (uncapped) with carboxylic acids end
groups showed faster drug release than RG 752S (capped) hav-
ing alkyle end groups. Because of the uncapped nature of RG
752H, it is relatively more polar than RG 752S. Thus, it leads
to a higher afﬁnity to the hydrophilic buffer solution, resulting
in a faster solvent diffusion from the polymer solution and
polymer precipitation and, hence, faster drug release (Fig. 2).
Tween 80 increases the differences, which are statistically
signiﬁcant (P< 0.05), between these two resomers. The pre-
cipitation of PLGA followed a biphasic mechanism. Immedi-
ately after injection a thin PLGA shell is formed. NMP and
buprenorphine HCl dissolved in it diffused through the shell
membrane into aqueous environment, while water diffused in-
side. At the same time the membrane matrix increased and
buprenorphine HCl precipitated and immobilized within the
membrane matrix. Furthermore buprenorphine HCl is located
in an aqueous environment which is created via water penetra-Table 2 In vitro kinetics model of buprenorphine HCl released fro
Zero order plotsa R2 First order plot
RG752 H (10%Tween) 0.428 0.733
RG752 S (10%Tween) 0.518 0.655
RG752 H (0%Tween) 0.809 0.812
RG752 S (0%Tween) 0.674 0.667
a Zero order equation: Qt ¼ K0t.
b First-order equation: logQt ¼ logQ0  K1t=2:303.
c Higuchi’s equation: Qt ¼ KH  t1=2.
d Korsmeyer–Peppas equation: QtQ1
¼ atn.tion inside the membrane. After increasing the solidiﬁcation of
the PLGA and further precipitation of the polymeric mem-
brane the diffusion distances increases. According to the Ein-
stein–Smoluchowski equation (1), where D is the diffusion
coefﬁcient, d the distance and t the time, with increasing diffu-
sion distances inside the membrane, the time for diffusion of
NMP outside and water inside the membrane increased
(Atkins, 1990; Kempe et al., 2008).
D ¼ d
2
2t
! t ¼ d
2
2D
ð1Þ
Both RG 752S and RG 752H experienced faster drug release in
presence of Tween 80, as well as both of them showed higher
initial release (Figs. 2 and 3). This faster drug release in pres-
ence of Tween 80 was due to the solubilizing characteristics
of Tween because of a reduced interfacial tension between
the solidiﬁed polymer and buffer solution. This may have en-
hanced the water penetration into solidiﬁed polymer and the
increasing of membrane pore size. As a result, the diffusion
of buprenorphine HCl and its solubility into the buffer in-
creased. The amount of buprenorphine HCl released in the ini-
tial burst phase was increased by about 5.0 and 3.8 times at
formulation containing RG 752H and RG 752S with Tween
80, respectively.
The lower initial release from membrane made of RG 752S
correlated well with a slower NMP diffusion rate from the sys-
tem compared to membrane prepared with the high polar RG
752H. This could possibly be attributed to the stronger inter-
actions between polar solvent NMP and the more hydrophilic
polymer RG 752H (with carboxyl end groups, when compared
to RG 752S). The cumulative amount of buprenorphine HCl
released (31.75 ± 1.59%) for RG 752H and (10.67 ± 1.31%)
for RG 752S over the ﬁrst 24 h (burst phase) in presence of
Tween 80 (10% w/w), was signiﬁcantly (P< 0.05) higher than
formulation without Tween 80 (6.18 ± 0.86%) for RG 752H
and (2.83 ± 0.55%) for RG 752S, respectively.
To understand the kinetics of the drug release from ISF
formulations, the data were ﬁtted to zero order (cumulative
amount of drug released vs time), ﬁrst-order (log cumulative per-
centage of drug remaining vs time), Higuchi (cumulative
percentage of drug released vs square root of time), and
Korsmeyer–Peppas (log cumulative percentage of drug released
vs log time) kinetic models. As shown in Table 2, the formula-
tions do not comply with zero and ﬁrst order release. However
the release rates are very good linearity in Higuchi and
Korsmeyer–Peppas equations. The exponent n revealed thatm in situ gel forming.
sb R2 Higuchi plotsc R2 Korsmeyer–Peppas plotsd
R2 n
0.943 0.997 0.135
0.917 0.986 0.191
0.994 0.991 0.307
0.945 0.986 0.284
260 S. Koocheki et al.the drug release is a combination of the Fickian diffusion (Basak
et al., 2008) and erosion (Shoaib et al., 2006) mechanisms.
Table 3 reports the Tg values when observed for the mem-
branes made with the 2 polymers at different Tween contents
(Fig. 4). Amorphous polymers are characterized by glass tran-
sition temperature (Tg), which is the transition point between a
highly viscous brittle structure called glass and a less viscous,
more mobile, rubbery state. The rubbery state (above the
Tg), represents a liquid like structure with high molecular
mobility and is thus more prone to physical and chemical
changes than the glassy state. The Tg value of a glassy polymer
can be modiﬁed by blending with a small amount of a low
molecular weight substance. Plasticization occurs when a small
molecule, called a plasticizer, blended with a glassy polymer
results in a decrease of the Tg of the polymer and its elasticFigure 4 DSC proﬁles of (A) RG 752H and (B) RG 752S with
different ratios of Tween 80.
Table 3 Glass transition temperature of PLGA membranes
containing different amounts of Tween 80.
Tween 80 (%) Tg (C)
RG752H RG752S
0 44.2 ± 0.7 46.5 ± 0.5
5 37.6 ± 0.4 39.8 ± 0.8
10 32.4 ± 0.8 38.5 ± 0.6
15 31.8 ± 0.6 37.8 ± 0.5modulus. Such plasticization normally increases polymer
ﬂexibility or mobility. Therefore, the performance of a poly-
mer membrane can be modiﬁed in the presence of a plasticizer,
or another substance, depending on the nature of the associa-
tion between the various phases (Blasi et al., 2005). The RG
752H and RG 752S blank membranes had a Tg of 44 C
and 46 C, respectively (Table 3); by adding Tween to the poly-
mers, a Tg reduction was observed and the transition became
less pronounced (Table 3). Tween seems to act as a plasticizer
within the membrane matrix. The maximum plasticizing effect
was observed with 10% and 5% (wt/wt) of Tween for RG
752H and RG 752S, respectively. This ﬁnding indicates that
Tween miscibility into the RG 752H polymer is higher than
RG 752S and it is because of interaction between polyether
head group of Tween and carboxylic acid head group of RG
752H which for both polymers was limited.
The membranes were further characterized by XRD (Fig. 5)
(all data not shown). The XRD pattern of pure PLGA and
buprenorphine HCl shows amorphous and crystalline charac-
teristics, respectively. Drug peaks in membrane were dimin-
ished because the drug is diluted in high concentration of
polymer. It seems the degree of crystallinity is decreased after
phase inversion which helps the dissolution of drug from mem-
brane. It reveals the drug entrapped in matrix of membrane
and small quantity of drug located on the surface; this can
be attributed to burst release of drug (Figs. 2 and 3). This is
in accordance with previous studies (Agnihotri and Vavia,
2009; Himanshu et al., 2010; Pignatello et al., 2002).
The morphologies of membranes with and without Tween
are shown in SEM micrographs of Figs. 6 and 7. Figs. 6A
and 7A show the morphologies of RG 504H of various cross-
linking ratios after swelling without and with Tween 80,
respectively. The pictures clearly show that the typical porous
structures are present and the corresponding pore sizes are lar-
ger at lower crosslinking ratios. Membranes from RG 752H
had a very porous inner structure.
Figs. 6B and 7B show the corresponding morphologies of
RG 504S crosslinking after swelling with and without Tween
80, respectively. Evidently, the pore sizes without Tween 80
are nearly the same as with Tween 80. The slower solvent dif-
fusion rate resulted in a denser structure with RG 752S
(Figs. 6B and 7B). This is in accordance with the release proﬁle
presented at Figs. 2 and 3.Figure 5 XRD diffractograms: RG 752H, RG 752S, buprenor-
phine HCl and membrane.
Figure 6 The morphology of RG 752H (A) and RG 752S (B) without Tween 80 at magniﬁcation of 1000.
Figure 7 The morphology of RG 752H (A) and RG 752S (B) with Tween 80 at magniﬁcation of 1000.
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This study showed the inﬂuence of Tween 80 as a rate modify-
ing additive on polar PLGA for in situ forming biodegradable
membrane preparation. The release rate of buprenorphine HCl
can be changed to a faster manner using RG 752H and 10%w/
w of Tween 80. This increasing rate can be related to the reduc-
ing interfacial tension between the in situ implant and buffer
solution, which may have enhanced the water penetration into
the implant, hence increases the diffusion of buprenorphine
HCl and its solubility into the buffer. PLGA with free alkyl
end groups led to a lower drug release compared to PLGA
with carboxylic acid end groups in presence of Tween 80
(10% w/w). A slower solvent diffusion from the low-polar
PLGA into the release medium creates a less porous structure
of the resulting membrane, thus explaining the lower initial
burst release. Membrane from RG 752H and Tween 80
(10% w/w) has a very porous inner structure. Finally, these
four developed formulations based on biodegradable mem-
brane and 10% w/w of Tween 80 can release different dose
of buprenorphine hydrochloride based on diffusion and ero-
sion mechanism which complies with the Korsmeyer–Peppaskinetic equation. These suggested formulations can be applica-
ble in treatment of opioid dependence, acute and chronic
pains. Further investigations and in vivo studies are required
for showing the efﬁcacy and consistency of developed formula-
tions in order to increase the application of buprenorphine
hydrochloride.Acknowledgment
The authors would like to thank the Exir Pharmaceutical Co.
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